Delcath Systems shows a confirmed technical breakout backed by a strong earnings-beat streak and excellent cash conversion, but light analyst coverage, high short interest, and proximity to its 52-week high leave the setup mixed.
Thesis pillars
- Breakout Momentum Golden Cross→Stable
- Strong Earnings Beat Streak→Stable
- Excellent Cash Conversion Quality→Stable
- +2 more pillars — see the Why tab for full reasoning
Delcath Systems, Inc. (DCTH) Stock Analysis
Breakout setup · Inst Constrain edge
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $13.10, but acceptable to hold if already in. Reasons: Concentration risk — Product: HEPZATO; Concentration risk — Supplier: melphalan supplier.
Delcath Systems is an interventional oncology company commercializing HEPZATO KIT, an FDA-approved liver-directed melphalan/device combination for adult uveal melanoma patients with hepatic metastases, and its European device-only counterpart, CHEMOSAT. The company posted a net... Read more
Hold if already holding. Not a fresh buy at $13.10, but acceptable to hold if already in. Reasons: Concentration risk — Product: HEPZATO; Concentration risk — Supplier: melphalan supplier. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Mixed signals. Hold existing position. Score 6.5/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 31d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
About Delcath Systems, Inc.
About Delcath Systems, Inc.
Delcath Systems' lead product, HEPZATO KIT, won FDA approval in August 2023 as a liver-directed treatment for adult uveal melanoma patients with unresectable hepatic metastases, with first commercial use in January 2024, and the company posted a net gain of approximately $2.7 million in 2025 after a $26.4 million net loss in 2024. In Europe, the same hepatic delivery system sells as the CHEMOSAT device, which received Medical Device Regulation certification in February 2022. The company held $43.5 million in cash and equivalents and $47.6 million in short-term investments as of December 31, 2025, and operates as a single reporting segment.
Delcath earns revenue from HEPZATO sales to U.S. cancer centers that complete Risk Evaluation and Mitigation Strategy training, and from CHEMOSAT device sales in Europe, where physicians separately source melphalan for use with the device. The company manufactures its proprietary filter media and assembles and packages both products at its Queensbury, New York facility, with European finishing, assembly, and distribution handled from its Galway, Ireland headquarters. Melphalan, the chemotherapeutic drug at the core of both products, is sourced under an agreement with a single contracted supplier, while three approved melphalan manufacturers currently serve the European Union market. Delcath is also running Phase 2 trials combining HEPZATO with standard-of-care regimens in metastatic colorectal cancer and metastatic breast cancer, with primary hepatic progression-free survival readouts expected in 2027 and 2028, respectively.
Show full overview
Delcath's commercial supply chain concentrates on a single counterparty: the 10-K states that the company currently has an agreement with one supplier of melphalan and is in discussions with other abbreviated NDA holders to reduce the risk of a supply interruption. Because HEPZATO and CHEMOSAT cannot be manufactured or sold without a continuous melphalan supply, and FDA inspections of that supplier for products made for other customers could shut down or delay its ability to deliver components, a single adverse regulatory finding at that one facility -- rather than any change in HEPZATO's clinical profile -- could halt commercial sales of both products simultaneously.
See also: Healthcare · Medical Devices
From Delcath Systems, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductHEPZATO10-K Item 1A: 'Our ability to become and remain profitable is heavily dependent on our ability to generate substantial revenue from HEPZATO for the treatment of mUM.'
- HIGHSuppliermelphalan supplier10-K Item 1A: 'We currently have an agreement with one supplier of melphalan'
Material Events(8-K, last 90d)
- 2026-05-14Item 5.02LOWAt the May 13, 2026 annual meeting, stockholders approved an amendment to the 2020 Omnibus Equity Incentive Plan increasing available shares by 1,800,000. Routine plan amendment; no departure or appointment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $13.10, but acceptable to hold if already in. Reasons: Concentration risk — Product: HEPZATO; Concentration risk — Supplier: melphalan supplier. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Mixed signals. Hold existing position. Target $18.58 (+41.8%), stop $12.28 (−6.7%), A.R:R 2.7:1. Score 6.5/10, moderate confidence.
Take-profit target: $18.58 (+40.8% upside). Target $18.58 (+41.8%), stop $12.28 (−6.7%), A.R:R 2.7:1. Stop-loss: $12.28.
Concentration risk — Product: HEPZATO; Concentration risk — Supplier: melphalan supplier; Near 52-week high (1.8% away).
Delcath Systems, Inc. trades at a P/E of 1320.0 (forward -25.9). TrendMatrix value score: 8.2/10. Verdict: Hold.
13 analysts cover DCTH with a consensus score of 4.2/5. Average price target: $21.
What does Delcath Systems, Inc. do?Delcath Systems is an interventional oncology company commercializing HEPZATO KIT, an FDA-approved liver-directed...
Delcath Systems is an interventional oncology company commercializing HEPZATO KIT, an FDA-approved liver-directed melphalan/device combination for adult uveal melanoma patients with hepatic metastases, and its European device-only counterpart, CHEMOSAT. The company posted a net gain of approximately $2.7 million in 2025 after a $26.4 million net loss in 2024, and depends on a single contracted supplier for melphalan, the chemotherapeutic drug core to both products.